small molecule

WEGOVY

SEMAGLUTIDE

Loss of exclusivityFebruary 2041latest FDA-listed patent expiry

CompanyNOVO NORDISK INC

Drug detail

Brand name	WEGOVY
Active ingredient	SEMAGLUTIDE
Strength	1.7MG/0.75ML (1.7MG/0.75ML)
Dosage form	SOLUTION
Route	SUBCUTANEOUS
Modality	Small molecule
FDA approval	June 2021
Marketing status	RX

Listed patents

Patent	Expires	Type
11318191	February 2041	product
11478533	May 2040	use U-3861
11752198	August 2038	product
10888605	August 2038	product
12214017	August 2038	product
9764003	June 2033	use U-3161
8129343	December 2031	substance, product
8536122	March 2026	substance, product

Regulatory exclusivity

Code	Expires
I-973	August 2028
I-935	March 2027
D-190	July 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from NOVO NORDISK INC